Rocky Mountain Biosystems, Inc. (Wheat Ridge) announced receipt of a $600,000 Phase II SBIR grant from the NIH’s National Institute of Allergy and Infectious Diseases enabling continued work on their Self-Administered Vaccine Electromechanical (SAVE) technology. SAVE is a very smart, needle free, wristwatch-sized transdermal vaccine delivery technology system. This device-based platform rather uniquely enables one to self-administer a vaccine which in the event of a pandemic may enable large populations to achieve immunization against a threat in a reduced amount of time. Other potential benefits may include storage, supply and stability issues, as well as potential therapeutic delivery options. RMBI’s lead indications for SAVE are in the delivery prophylactic protection against influenza and pandemic flu.
***NOTE*** Take a look at the new Boulder Biotech Company Tree (HERE)!
***NOTE*** Read the new eBook CLSDF 2007 - What's In A Year? (HERE)!
If you enjoyed this post get free email or RSS updates (here).